New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:24 EDTINSMInsmed data likely supports accelerated approval in NTM, says Piper Jaffray
Piper Jaffray believes Insmed's data for Arikayce in nontuberculous mycobacteria is likely to support accelerated approval, especially if the relapse rate is modest. Piper says recent data for Arikayce has caused "considerable controversy" and it reiterates an Overweight rating on shares of Insmed.
News For INSM From The Last 14 Days
Check below for free stories on INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for INSM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use